XORTX Therapeutics Inc.
XRTX Nasdaq· Pharmaceutical Preparations
Last close · Nov 9, 2026
$0.85
Key numbers, fiscal 2025
Market cap
$4.0M
P/E
—
Revenue
—
Net income
−$2.7M
Free cash flow
—
Operating margin
—
XORTX Therapeutics Inc. in 30 seconds fiscal 2025
Does it make a profit?
−$2.7M
No. It lost money last year.
How long would its cash last?
0.3 yrs
Not long. It burns $2.8M a year and holds $0.9M, under a year at that pace, so it may need new money soon.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What XORTX Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 20, 2026
- Legal name
- XORTX Therapeutics Inc.
- CIK
- 0001729214
XORTX Therapeutics Inc. · XRTX · stoqly.net
Results and finances
The last 3 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$2.2M | −$3.3M | −$2.7M |
| Diluted EPS | −$1.09 | −$1.15 | −$0.56 |
| Cash | |||
| Cash from operations | −$6.6M | −$3.7M | −$2.8M |
| Capital expenditure | $0.0M | — | — |
| Free cash flow | −$6.6M | — | — |
| Share count change | — | 45.3% | 64.5% |
| Debt and strength | |||
| Cash and short-term investments | $3.4M | $2.5M | $0.9M |
| Shareholders' equity | $4.6M | $3.3M | $2.1M |
| Returns and quality | |||
| Return on equity | −46.5% | −83.1% | −98.0% |
| Return on tangible equity | −46.5% | −99.3% | −127.4% |
Insider trades 12 months
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
XORTX Therapeutics Inc. · XRTX · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001729214). Latest version: stoqly.net/companies/xrtx. Data updated November 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.